Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 9:6:104.
doi: 10.3389/fvets.2019.00104. eCollection 2019.

In vitro Effect of Recombinant Feline Interferon-Ω (rFeIFN-Ω) on the Primary CanineTransmissible Venereal Tumor Culture

Chanokchon Setthawongsin  1 , Sirikachorn Tangkawattana  2 , Anudep Rungsipipat  1 , Somporn Techangamsuwan  1
Affiliations

In vitro Effect of Recombinant Feline Interferon-Ω (rFeIFN-Ω) on the Primary CanineTransmissible Venereal Tumor Culture

Chanokchon Setthawongsin et al. Front Vet Sci. .

Abstract

Background: Interferons (IFNs), signaling proteins produced by host cells, are secreted in response to pathogen activity as well as to tumor cells, and display antiviral, antiproliferative, and immunomodulatory effects. Recombinant feline interferon omega (rFeIFN-ω) has in vitro growth inhibition activities on various canine and feline tumor cell lines. Canine transmissible venereal tumor (CTVT) is used as an animal model for immunotherapy due to its specific growth phase. Previous studies have usually focused on the interaction between tumor infiltrating lymphocytes (TILs) and CTVT cells. However, the specific effects of rFeIFN-ω on CTVT cells remains poorly defined. Aims: The aims of this study, therefore, were to evaluate the in vitro effect of rFeIFN-ω on primary CTVT cells and to study the mRNA expression of apoptotic genes and drug resistance genes. Materials and Methods: Purified CTVT cells were treated with various concentrations of rFeIFN-ω and the viability of the cultured cells was ascertained at 24, 48, and 72 h post treatment (hpt) and a dose-response curve plotted. The mRNA expression of apoptotic (BAX and BCL-2) and drug resistance (ABCB1 and ABCG2) genes was performed by reverse transcription quantitative real-time PCR at 72 hpt. Results: rFeIFN-ω displayed an effect against CTVT cell viability, which decreasing viability in a dose-dependent manner within 72 hpt. The relative mRNA expression of BCL-2 was upregulated only at a rFeIFN-ω concentration of 104 IU/100 μl. However, higher concentrations of rFeIFN-ω gave a higher level of relative mRNA expression of ABCB1 transporter gene. Conclusion: This study provided the information of in vitro effect of rFeIFN-ω on CTVT cell viability in a dose dependent manner, as well as, the alteration of BCL-2 and ABCB1 gene expression after treatment. These results encourage future in vivo studies to evaluate the potential efficacy of this treatment in CTVT cases.

Keywords: CTVT; in vitro study; interferon; primary culture; rFeIFN-Ω.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A dose responsive curve between rFeIFN-ω and cell viability at 24 (A), 48 (B), 72 (C) hours after treatment. (*p < 0.05; **p < 0.01).
Figure 2
Figure 2
Box plot showed the relative mRNA expression of BCL-2(A), BAX (B) gene, and the relative BCL-2/BAX ratio (C) of primary CTVT culture at 72-h after incubation with varied concentrations of rFeIFN-ω (*p < 0.05; ***p < 0.001).
Figure 3
Figure 3
Box plot showed the relative mRNA expression of ABCB1 (A) and ABCG2 (B) gene of primary CTVT culture at 72-h after incubation with varied concentrations of rFeIFN-ω (*p < 0.05).
See this image and copyright information in PMC

References

    1. Tizard IR. Veterinary Immunology: An Introduction. Missouri, MO: Saunders; (2000). 141 p.
    1. Berry CM. Understanding interferon subtype therapy for viral infections: harnessing the power of the innate immune system. Cytokine Growth Factor Rev. (2016)31:83–90. 10.1016/j.cytogfr.2016.08.001 - DOI - PubMed
    1. Hauptmann R, Swetly P. A novel class of human type I interferons. Nucl Acid Res. (1985) 13:4739–49. 10.1093/nar/13.13.4739 - DOI - PMC - PubMed
    1. Klotz D, Baumgärtner W, Gerhauser I. Type I interferons in the pathogenesis and treatment of canine diseases. Vet Immunol Immunopathol. (2017) 191:80–93. 10.1016/j.vetimm.2017.08.006 - DOI - PubMed
    1. Himmler A, Hauptmann R, Adolf GR, Swetly P. Structure and expression in Escherichia coli of canine interferon-α genes. J Interferon Res. (1987) 7:173–83. 10.1089/jir.1987.7.173 - DOI - PubMed